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Abstract: Glia form a central component of the nervous system whose varied activities sustain
an environment that is optimised for healthy development and neuronal function. Alpha-amino-
3-hydroxy-5-methyl-4-isoxazole (AMPA)-type glutamate receptors (AMPAR) are a central mediator
of glutamatergic excitatory synaptic transmission, yet they are also expressed in a wide range of
glial cells where they influence a variety of important cellular functions. AMPAR enable glial cells
to sense the activity of neighbouring axons and synapses, and as such many aspects of glial cell
development and function are influenced by the activity of neural circuits. However, these AMPAR
also render glia sensitive to elevations of the extracellular concentration of glutamate, which are
associated with a broad range of pathological conditions. Excessive activation of AMPAR under
these conditions may induce excitotoxic injury in glial cells, and trigger pathophysiological responses
threatening other neural cells and amplifying ongoing disease processes. The aim of this review is to
gather information on AMPAR function from across the broad diversity of glial cells, identify their
contribution to pathophysiological processes, and highlight new areas of research whose progress
may increase our understanding of nervous system dysfunction and disease.
Keywords: glia; AMPA receptor; astrocyte; microglia; glutamate; excitotoxicity; inflammation;
hypoxia; ischemia; multiple sclerosis; neurodegeneration
1. Introduction
Glutamatergic signaling through alpha-amino-3-hydroxy-5-methyl-4-isoxazole (AMPA) receptors
(AMPAR) forms a major component of excitatory synaptic transmission in the central nervous system
(CNS). However, glutamate release in the CNS is not exclusive to synaptic terminals, but also
arises from unmyelinated axons [1] and non-neuronal glial cells [2] under both physiological and
pathophysiological conditions. Glutamate is therefore present at varying concentrations in a number
of extra-synaptic locations where it influences non-neuronal AMPAR, particularly those expressed by
CNS glia cells, leading to influences on a range of critical functions. Importantly, glutamate release is
enhanced under a number of pathological conditions [3–5] leading to concentrations of extracellular
glutamate that trigger excitotoxic processes that threatens glial cell viability, and set in motion cellular
and molecular processes that initiate and intensify pathophysiological conditions. In this review
we provide an overview of AMPAR expression in glial cells of the CNS and peripheral nervous
system (PNS), describing functions for these receptors in physiological conditions, highlighting their
involvement in glial responses to pathophysiological conditions, and hypothesising on additional roles
that glial AMPAR may perform in the context of nervous system injury and disease. The review will also
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indicate areas for future research, including cannabinoid AMPAR interactions, and AMPAR-stimulated
transcriptional regulation, whose investigation promises to stimulate new knowledge on mechanisms
regulating injury and disease processes, and identify new targets for CNS protection and repair.
1.1. Glia: A Brief Overview of Diversity in Form and Function
Glia are a diverse group of neural cells whose principle uniting features are a non-neuronal
identity, and the performance of functions essential to the normal operation of the nervous system.
Glia can be divided into two categories based on their developmental origins: macroglia derived from
the ectoderm; and microglia derived from hemopoietic stem cells originating from the yolk sac during
early embryonic development [6]. The principle CNS macroglia are the astrocytes and oligodendrocytes
(OL). Astrocytes are a heterogenous group of cells that, in addition to a well-defined role in optimising
extracellular conditions for neuronal function via the uptake of neurotransmitters and ions, may also
contribute to the regulation of a number of other functions including synaptic function, cerebral blood
flow and maintenance of the blood brain barrier [7]. OL are exclusively involved in myelin generation
in the CNS [8]. However, it is now appreciated that myelination provides benefits to their neuronal
targets that extend beyond the enhancement of axonal conduction velocities to encompass the provision
of trophic and metabolic support [9], and potentially an involvement in information processing and
and learning [10,11]. CNS macroglia also include NG2-glia, radial glia, and ependymal cells. NG2- glia
are characterised as multi-process bearing NG2/PDGF receptor α expressing cells capable of generating
OL and astrocytes (and possibly neurons, although this is the subject of intense debate [12]) in both
the embryonic and postnatal CNS [13]. However, their extensive distribution throughout the adult
CNS, and synaptic integration with neural circuity, suggest functions that extend beyond the role of
a glial progenitor [13–15]. Radial glia are astrocyte-like neural progenitors that sequentially give rise
to neurons, astrocytes and OL during embryonic development [16]. They are also considered to be
the progenitors for the CNS ependymal cells (see below) [17]. Structurally, radial glia are polarised
cells with a cell body located close to the ventricle, a short “endfoot” oriented towards the ventricle
wall, and a longer process that extends to make contact with the pial surface [18]. This morphological
arrangement provides a scaffold that guides newly born neurons as they migrate into the developing
cerebral cortex [19]. Ependymal cells cover the brain’s ventricles and the central canal of the spinal
cord. Examples of ependymal cells include the cerebral spinal fluid secreting choroid plexus epithelial
cells [20], and thalamic tanycytes. Tanycytes are radial glia-like cells located in the walls of the 3rd and
4th ventricle, that exhibit a neuro- and gliogenic capacity, and through their function as glucosensors,
are proposed to play a role in regulating feeding and energy balance [21]. Microglia, which are
restricted to the CNS, present a dualistic identity, providing protective and modulatory influences
under healthy conditions through the release of pro-survival trophic factors, and by tidying CNS
tissues through the removal of dead cells and the pruning of excess synapses. However, when activated
under pathological conditions they play a central role in the progression of CNS injury and disease
states through the release of inflammatory and cytotoxic mediators [22]. Thus, microglia are essential
to both the maintenance of a healthy CNS environment, and the pathophysiological processes that
threaten it.
PNS macroglia include Schwann cells, satellite cells and enteric glia. Schwann cells exhibit two
forms, the myelinating variety which form compact myelin sheaths on PNS axons, and non-myelinating
forms whose interactions with multiple axons form the Remak fibres [23]. Under pathological
conditions Schwann cells are capable of de-differentiating into an immature phenotype reported
to exhibit pro-demyelination characteristics, while also expressing neurotrophic factors involved in
neuronal survival and axonal regeneration [24]. Satellite glia interact with the soma of neurons in the
sensory, sympathetic and parasympathetic ganglia where they are considered to play a similar role
to astrocytes in the CNS. Finally, enteric glia are located in the ganglia of the gastrointestinal tract
and are considered the most similar of PNS glia to astrocytes due to their multi-process morphology,
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including “end feet” connected to blood vessels, and their coupling via gap junctions to form a glial
syncytium [25].
1.2. AMPAR
AMPAR are one of three types of ionotropic glutamate receptors, the others being the
N-methyl-d-aspartate receptors (NMDAR), known for their involvement in synaptic plasticity [26], and
the kainate receptors (KR). KR are frequently grouped with AMPAR due to their similar pharmacological
properties (e.g., agonised by kainate, and antagonised by several of the same drugs). However, KR
are formed from distinct protein subunits that confer unique receptor properties, such as slower
inactivation kinetics, that distinguish them from AMPAR [27,28]. Although glutamate can influence
glia via activation of NMDAR and KR, these actions have been reviewed elsewhere [29,30] and
will not be covered in the present work. Regarding AMPAR function in neuronal circuits, AMPAR
activation mediates the majority of fast excitatory synaptic communication in the CNS. AMPAR are
heterotetrameric complexes containing various combinations of the pore forming GluA subunits 1–4
(GluA1–4) whose assembly produces cation permeable receptors with physiological properties that
differ depending on their specific subunit composition [28]. AMPAR channel activation permits the
influx of Na+, and varying levels of Ca2+, depending on the subunits present in the complex. Cation
influx induces excitatory post synaptic currents (EPSCs) with rapid kinetics that are characterised by
pronounced receptor desensitisation and influenced by subunit composition [31,32]. The inclusion
of GluA2 limits the permeability of AMPAR to Ca2+ due to codon editing at the so-called Q/R site
located within the pore forming region. The vast majority of GluA2 subunits undergo Q/R editing
leading to the presence of a positively charged arginine residue within this region that inhibits the
permeation of divalent ions [33,34]. In this way, AMPAR lacking GluA2 show greater Ca2+ permeability
than complexes containing this subunit. Variation in AMPAR desensitisation of all GluA subunits
arises through alternative splicing to produce Flip and Flop variants that differ in their kinetics of
desensitisation [28]. Importantly, most Flip variants exhibit slower, less pronounced, desensitisation,
thus a dominance of these subunits over the Flop variant in AMPAR would be expected to increase
vulnerability to excitotoxic injury. This scenario may occur in amyotrophic lateral sclerosis (ALS) where
motoneurons in the cervical ventral horn show a decrease in Flop variants, while Flip expression is
sustained [35]. Diversity in AMPAR receptor function is also provided by a range of auxiliary proteins,
most notably the transmembrane AMPAR regulatory proteins (TARPs), whose inclusion in the complex
influences AMPAR pharmacology and kinetics, and regulates GluA subunit trafficking [36,37].
AMPAR function in the nervous system is not restricted to neuronal cells. Indeed many glial
cells exhibit functional AMPAR whose activation regulates a range of important cellular activities
including cell migration [38,39], morphological development and re-structuring [40,41] proliferation
and differentiation [42,43], transcriptional regulation [44,45], survival [46], and the regulation of various
ion channels [42,47,48]. Importantly, overactivation of AMPAR plays a key role in mediating cellular
injury to neuronal and glial cells alike. These excitotoxic actions, which largely depend on the excessive
influx of Ca2+, are described in the following section.
1.3. AMPAR Involvement in Cellular Injury
Glutamatergic excitotoxic injury is defined by the overactivation of glutamate receptors due to
high or prolonged glutamate exposure. Cell death induced by excitotoxicity is an important feature in
either acute or neurodegenerative pathologies [4,49]. After an ischemic stroke the increase of glutamate
level directly correlates to the severity of the stroke, infarct volume and poorer functional outcome
of patients [50,51]. That correlation has also been observed in different rodent stroke models [52].
Similar results were observed in the cerebrospinal fluid (CSF) or cerebral areas of patients after
a traumatic brain injury [53,54]. Higher levels of glutamate have also been described in the CSF of
infants correlating with the severity of hypoxic-ischemic (H-I) encephalopathy [55], and indeed levels
of glutamate remain elevated for days in animal models of pre-term H-I injury [56–58]. Glutamate
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excitotoxicity is also an important event in chronic neurodegenerative diseases [49]. Both Parkinson’s
and Alzheimer’s diseases are characterized by a dysregulation of glutamate homeostasis that may
damage neurons [59–61], and both serum and CSF from patients with Multiple Sclerosis (MS) and
Amyotrophic Lateral Sclerosis (ALS) show higher levels of glutamate [5,62,63].
Excessive levels of glutamate induce cell death by several complex mechanisms that have been
previously reviewed [49,60,64]. Importantly, sustained activation of AMPAR, NMDAR and KR under
these conditions produce a large increase in intracellular Ca2+ [65–67] that triggers various cellular injury
processes including endoplasmic reticulum (ER) stress, mitochondrial dysfunction and the production
of reactive oxygen and nitrogen species [59,66,68–75]. Ca2+ influx also induces the activation of
calcium-dependent enzymes that promote cell damage. This situation is exemplified by calpain, whose
activation by elevated Ca2+ levels promotes the internalization of plasma membrane Ca2+ ATPase
leading to further dysregulation of intracellular Ca2+ and oxidative stress [68,76,77]. These outcomes
are related to ER stress since this organelle is highly sensitive to disturbances in calcium homeostasis
and the reactive species that ensue under these conditions. Therefore, the ER is highly sensitive to
glutamate insults and cytosolic Ca2+ elevations [68,69,71,78,79]. In addition to these actions, calpain
may actively promote ER stress via the modulation of ryanodine receptor and the sarco/endoplasmic
reticulum Ca2+-ATPase (SERCA) [71,80–82]. Here, alterations in ryanodine receptors and the SERCA
produce further dysregulation of the Ca2+ balance providing an additional stimulus to the production of
reactive oxygen species, which, together with reactive nitrogen species that also arise due to enhanced
Ca2+ levels, promote oxidative stress [64,68,69,72,77,80,83,84]. Ca2+ accumulation and nitrogen oxide
disrupt the electron transport chain in mitochondria producing additional reactive oxygen species and
mitochondria dysfunction [64,68,77]. Indeed, glutamate induction of both mitochondria failure and ER
stress are critical factors in excitotoxic cell death [59,64,68,69,74,77]. Glutamate insult further potentiates
oxidative stress by decreasing glutathione and superoxide dismutase activity, and promoting NADPH
oxidase activity, eventually leading to lipid peroxidation, protein nitrosylation and cell death [72,85].
In addition, glutamate excitotoxicity also increases Ca2+ uptake by mitochondria, leading to the opening
of mitochondrial permeability transition pores, and mitochondria fragmentation [66,74]. The high levels
of Ca2+ uptake by mitochondria have also been related to the inhibition of mitochondrial respiration
and the release of cytochrome c, thus triggering apoptosis [75,86,87]. Glutamate excitotoxicity also
increases the expression of pro-apoptotic Bak protein, while also decreasing anti-apoptotic Bcl-2 protein
levels [71], and altering the transcription and function of the nuclear factor Y (NF-Y) complex [45],
a transcription factor closely linked to the control of apoptotic cell death [88] (see Section 8).
1.4. AMPAR in Glial Cells
The vast majority of research into glial cells has focussed on the astrocytes, oligodendrocytes and
microglia. Much is therefore known regarding the expression and function of AMPAR in these CNS
glia, while knowledge on this topic in other glial cells, particularly those of the autonomic system and
the ependymal tissues is limited. Consequently this review will largely focus on those glia where
functional AMPAR have been most thoroughly explored, although we will attempt to summarise the
information that is available on other glial subtypes where possible. The following sections provide
a review of each glial cell type, considering AMPAR expression, describing the known functions for
these receptors in physiological and pathophysiological conditions, and highlighting emergent actions
that stimulation of these AMPAR may evoke in the context of nervous system injury and disease.
The major findings on AMPAR receptor expression and function in each glial cell type are summarised
in Tables 1–4.
2. Astrocytes
Astrocytes are the most numerous glial cells in the CNS. They are distributed throughout both
the grey and white matter where they perform a myriad of tasks that serve to maintain neuronal
function. Astrocytes make extensive contacts with synapses and nodes of Ranvier that enable them
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to regulate neuronal environments. They achieve this through the re-uptake of transmitters, and
the buffering of extracellular ions, which together help to provide an extracellular environment that
is optimised for efficient axonal and synaptic activity. In addition to their connections to neuronal
compartments, astrocytes extend processes that terminate on cerebral vasculature through which they
are involved in the formation of the blood brain barrier [89], and in mediating neurovascular coupling
to maintain the supply of energy to the brain [90]. Astrocytes also have important functions in guiding
CNS development, being involved in both the regulation of myelination [91] and synaptogenesis [92].
Astrocytes are equipped with a diverse array of neurotransmitter receptors that enable them to
monitor neuronal activity, and which may provide the capacity to generate feedback signals via
“glio transmitters” whose actions on adjacent neuronal synapses may involve the regulation of basal
transmission and the regulation of synaptic plasticity [93] (also see [94]). Many of these neurotransmitter
actions, including those stemming from glutamate, are associated with the activation of metabotropic
receptors [95]. In contrast, less is known regarding the influence of AMPAR in astrocytes. The following
sections will review the available literature and discuss the potential functions of astrocyte AMPAR in
physiological and pathophysiological conditions. A summary of these findings is presented in Table 1.
Table 1. Summary of AMPAR expression and functions in astrocytes.
Region GluA Expression Ca
2+ Permeability Functions
Degree Evidence Physiological Pathophysiological
Cb GluA1, GluA4 [96] ++ ePhys [96]
Synapse
modulation [40]
Blockade of K+
currents [97]
Altered motor
control [98]
GLAST
downregulation [99]
Ctx GluA2 dominant(qPCR) [100] +/− Ci [101]
Regulate K+
currents [48] Excitotoxicity [101]
Hp
GluA2 dominant
(qPCR) [100]
No expression
(ephys) [102]
No AMPA
current ePhys [102] N.D. N.D.
OB GluA1, 2, 4 (IHC) [103] + ci, ePhys [103] N.D. N.D.
Th GluA1-4(RT-PCR) [104] +/− ePhys [104] N.D. N.D.
+/− low Ca2+ permeability; + intermediate Ca2+ permeability; ++ high Ca2+ permeability Cb: cerebellum; Ci: calcium
imaging analysis; ePhys: electrophysiological analysis; Ctx: cortex; Hp: hippocampus; IHC: immunohistochemistry;
N.D.: not determined; OB: olfactory bulb; qPCR: quantitative real-time PCR; RT-PCR: reverse transcription PCR;
Th: Thalamus.
2.1. Expression and Functional Properties of AMPAR in Astrocytes
Whole-cell voltage-clamp recordings show that astrocytes in most CNS regions exhibit
functional AMPAR [96,103–105]. The exception to this rule appears to be the hippocampus where
AMPAR-mediated currents are absent from astrocytes exhibiting high levels of GFAP-GFP transgene
expression (cells expressing low GFAP-GFP transgene are now recognised as oligodendrocyte
progenitors) [102]. The subunit composition of astrocyte AMPAR differs from region to region
leading to variability in their permeability to Ca2+. Bergmann glia in the cerebellum exhibit strong
expression of transcripts for GluA1 and GluA4, and lower levels of GluA2, leading to AMPAR with
a high level of Ca2+ permeability [40,96]. Similarly, astrocytes in the olfactory bulb (OB) express
significant levels of GluA1 and 4 protein, and low levels of GluA2 [103]. Although AMPA stimulation
evokes a measurable influx of Ca2+ in these cells, AMPAR-mediated currents in these astrocytes
are not fully blocked by specific blockade of Ca2+ permeable AMPAR, thus OB astrocytes appear to
express a mix of Ca2+ permeable and impermeable receptors [103]. In other CNS regions, such as the
cortex, GluA2 represents a dominant AMPAR subunit in astrocytes, with GluA1 and 4 transcripts
being present at considerably lower levels [100]. As expected, AMPAR stimulation fails to elicit Ca2+
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influx in cortical astrocytes unless their desensitisation is blocked by the application of cyclothiazide
(CTZ) [101] indicating a low permeability to Ca2+. In the spinal cord immunohistochemical analysis
reveals GluA2, 3 and 4 protein on GFAP+ astrocytes [106], while astrocytes in the thalamus exhibit
a low level of Ca2+ permeability, potentially due to a dominant expression of GluA2, as revealed by
the partial sensitivity of their AMPAR currents to pharmacological agents that selectively block GluA2
lacking receptors [104].
2.2. Astrocyte AMPAR Functions Under Physiological Conditions
Despite the abundance of studies exploring the expression of AMPAR in astrocytes (Section 2.2),
relatively few physiological functions are ascribed to these receptors. In vitro studies using primary
cultures of cortical astrocytes show that Na+ influx due to AMPAR activation produces a blockade of
outward K+ currents through both A-type and delayed rectifier channels [48]. AMPAR activation in
cultured Bergman glia produces similar effects on K+ currents activity [47,97]. Although this mechanism
has not been confirmed in situ, it has been proposed to act as a mechanism for limiting elevations in
extracellular [K+] during periods of excessive neuronal activity [48]. Astrocyte AMPAR are likely to be
situated in appropriate locations to fulfil this role since astrocyte processes make extensive contact with
synapses [92] and nodes of Ranvier throughout the CNS [107,108] (Figures 1A and 2A). Glutamate
has well documented effects on the function of peri-synaptic astrocytes [95], thus AMPAR-mediated
effects on outward K+ currents seems a possibility. With regard to peri-nodal astrocytes, internodal
axonal segments are known to release glutamate in an activity-dependent manner [109], yet it is
unclear whether glutamate released in this way diffuses in sufficient concentrations to stimulate glial
receptors located at nodes (Figure 1A). OL myelin). To do so it must cross the paranodal axoglial
junctions (PAJ) that separate the internodal periaxonal and paranodal spaces. The PAJ has in fact
been proposed as a route for the traffic of small molecules such as glucose [110], thus it is conceivable
that glutamate may also diffuse via this structure to reach glial AMPAR located in peri-nodal spaces.
Resolution of these questions could be achieved through the application of a genetically encoded
glutamate sensing molecule, for example the intensity-based glutamate sensing fluorescent reporter
(iGluSnFR) [111], which if targeted to astrocytes may be useful for revealing perinodal glutamate release.
Alternatively, two-photon imaging may be used to analyse AMPAR-mediated Ca2+ influx at peri-nodal
astrocyte process [112]. Studies of this nature could have wide-reaching impact given the important
role astrocytes play in the regulation of myelination [91], and the influence that neuronal activity
exerts in guiding oligodendrocyte differentiation and myelination [113]. Additionally, glutamate exerts
a multitude of action in astrocyte via metabotropic glutamate receptors [95], thus evidence in support
of an axonal-astrocyte glutamatergic signaling pathway could have significance for our understanding
of white matter development that extends beyond the influence of AMPAR.
In contrast to the hypothetical functions of white matter astrocytes discussed above, AMPAR
located on the processes of astrocytes in the molecular layer of the cerebellum perform an established
function in the regulation of excitatory synapses. Here, Ca2+ influx through Ca2+-permeable AMPAR
located on Bergman glial processes is linked to the regulation of glutamatergic synapses on Purkinje
cell dendrites [40]. These synapses are enfolded by Bergman glia processes [114] whose expression of
the glutamate transporter GLAST helps define the kinetics of AMPAR-mediated currents at Purkinje
cells synapses. The function of these Ca2+-permeable AMPAR, which lack GluA2, are revealed by
experiments in which the Ca2+ permeability of these AMPAR is reduced by exogenous expression
of GluA2. Forced GluA2 expression leads to a retraction of the glial processes away from synapses,
and an increase in the duration of Purkinje cell glutamatergic synaptic currents. These changes likely
reflect alterations in the re-uptake of glutamate by Bergmann glial glutamate transporters located on
the retracted processes [40]. Evidence for the significance of these synaptic effects are apparent in
observations from transgenic mice with astrocyte-targeted deletions of GluA1 and 4. Here, changes in
glial-neuron interactions and synaptic function are correlated with alterations in fine motor control
that are consistent with the disturbances in Purkinje cell synaptic function [98].
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Figure 1. AMPAR functions for CNS white matter glia in health and disease. (A) Illustration
depicting the interaction of glial elements in CNS white matter. Astrocytes (AST) and oligodendrocyte
progenitors (OPC) extend processes that make contact with unmyelinated axons and the nodes of
Ranvier on myelinated axons. These glial processes contain functional AMPAR since white matter
astrocytes exhibit AMPAR-mediated Ca2+ signals, and OPC display AMPAR-mediated synaptic
currents. Both unmyelinated and myelinated axons release glutamate via vesicular mechanisms.
Glutamate released at unmyelinated axons drives synaptic input on OPC, but it is unclear whether
glutamate released at internodal sites diffuses in concentrations sufficient to activate glial AMPAR at
nodes of Ranvier. The functional consequences of astrocyte AMPAR in white matter remains unknown
but may include a role in the regulation of outward K+ currents. AMPAR activation influences multiple
functions in OPC including migration, proliferation, differentiation and survival. In addition, AMPAR
activation in OPC influences events in the nucleus including the induction of immediate early genes
involved in cellular growth. Note, OPC actions depicted also occur in CNS grey matter. (B) Depiction of
excitotoxic events and glial cell injury in CNS white matter. Excitotoxic and in inflammatory conditions
involve an increase in extracellular glutamate levels that damage OL and myelin internodes. Glutamate
is released from damaged axons and from gap-junction hemichannels on activated microglia. Excessive
astrocyte AMPAR activation may aggravate excitotoxic conditions via the downregulation of astrocyte
GLAST. Myelin can be restored by OPC recruited to demyelinated axons. GluA2-GAPDH complexes
formed in astrocytes at inflammatory demyelinating lesions may undergo nuclear translocation leading
to the initiation of disease processes. Myelin repair involves the recruitment of OPC to demyelinated
axons where they establish AMPAR-mediated synaptic connections. Axon-OPC synapses may play
a role in guiding OPC to target axons, and in controlling their differentiation into myelinating OL.
The modulation of the Endocannabinoid System is able to prevent several of these pathogenic pathways.
Either the increase of endocannabinoid tone, or the direct agonism of CB1 receptors, reduces cytosolic
Ca2+ influx in the oligodendrocyte after an AMPA stimulus. Similarly, increased AEA tone prevents
GLAST and GLT-1 downregulation in a mechanism that involves at least CB1 receptor, and AEA tone
increase or CB1/ CB2 agonism potentiates GLAST and GLT-1 expression in mouse models of MS. Note,
other cytotoxic mediators involved in inflammatory demyelination, such as cytokines and complement
cascade components are not shown for clarity.
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2.3. Astrocyte AMPAR in Pathology
Astrocyte AMPAR activation has not been directly implicated in CNS injury or disease. Indeed,
in contrast to cells in the OL lineage (Section 3.2), astrocytes do not appear to be vulnerable to
pathological conditions associated with glutamate mediated excitotoxicity [106,115]. In fact, AMPAR
mediated excitotoxicity is only observed in cultures of cortical astrocytes when AMPAR desensitisation
is prevented by the application of CTZ [101]. Ca2+ imaging failed to reveal glutamate-mediated Ca2+
influx in these cultures suggesting that cortical astrocytes exhibit AMPAR with low Ca2+ permeability.
These findings, and similar observations of excitotoxic resistance in hippocampal astrocytes [116],
are supported by RNAseq data showing a dominance of GluA2 in both cortical and hippocampal
astrocytes in situ [100]. Thus, low levels of AMPAR Ca2+ permeability may be associated with resistance
to glutamate mediated injury. While excessive AMPAR activation does not appear to induce overt
injury, it may trigger molecular alterations that could then trigger pathological conditions in the CNS.
In this regard, prolonged stimulation of cultured Bergmann glia with AMPAR antagonists produces
a downregulation in the expression of the glutamate transporter GLAST [99] (Figure 2B). Alterations
in glial glutamate clearance due to a reduction in GLAST would be expected to disturb synaptic
transmission, and could intensify excitotoxic conditions thus threatening more vulnerable neurons and
OL. On this basis astrocyte AMPAR may represent a useful therapeutic target despite the apparent
insensitivity to glutamate mediated injury of these glia.
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Figure 2. AMPAR functions for peri-synaptic CNS glia in health and disease. (A) In the healthy CNS
astrocyte (AST) and OPC/NG2-glia processes ex ibit physical and functional contacts with neuronal
synapses. Ca2+ permeable AMPAR on B n glia sustain the physical interaction b tween glial
processes and neuronal synapses allowing effici nt clearance of glutamate from Purkinje cell synapses.
Activation of astrocyte AMPAR also induces a blockade of outward K+ currents that may support
neuronal function during sustained periods of neuronal activity. OPC/NG2-glia in developing and
adult CNS tissues exhibit Ca2+ permeable AMPAR and receive AMPAR-mediated synaptic input
that may regulate their migration, maturation and survival. In the adult CNS NG2-glia continue to
receive synaptic input, the functions of which remain unclear. The role of microglial AMPAR in the
healthy CNS remain unknown although in vitro data suggest a role in chemotaxis [117]. (B) Glial
cell AMPAR amplify pathological conditions and mediate glial cell injury in the CNS. Stimulation
of AMPAR under excitotoxic conditions induces the release of glutamate from activated microglia
via gap-j nction hemichannels. AMPAR activation un er hypoxic conditions also stimulates the
upregu tion f micr glial AMPAR leading to an imbalance in anti- and pro-inflamm tory cytokine
release characterised by enha ced release of TNF-α. TNF-α released from activated microgl a may
intensify excitotoxic conditions by inducing the downregulation of astrocytic GLT1. Similarly, direct
stimulation of astrocyte AMPAR may worsen excitotoxic conditions by inducing the downregulation of
GLAST. TNF-α also increases the vulnerability of neurons to excitotoxicity by stimulating increased
surface trafficking of AMPAR. Excessive AMPAR activation induces direct injury to OPC via numerous
mechanisms including oxidative and ER stress and mitochondrial dysfunction (depicted by red
organelles). In addition, excitotoxic stimulation of OPC AMPAR alters the function of transcription
factor complex NF-Y leading to alterations in the expression of Ca2+ permeable GluA4 subunits and
the regulation of genes involved in apoptosis.
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Excitoxicity is a common feature of many CNS disease states including H-I injury, stroke, multiple
sclerosis and neurodegenerative disorders including Alzheimer’s, Huntinton’s and Parkinson’s
Disease [118]. Thus, CNS diseases of this type may provide valuable areas in which to search for
subtle molecular alterations that could signal an involvement of astrocyte AMPAR in the initiation
or propagation of the disease state. In this context, the emergence of RNAseq studies examining
cell-specific gene expression in various disease models provides an opportunity to search for disease
signatures that could foreshadow an involvement of glial AMPAR. The experimental autoimmune
encephalomyelitis (EAE) model of inflammatory demyelination provides a promising model for this
line of enquiry since AMPAR-mediated excitotoxicity has been linked to disease processes in this
model [119–121]. In agreement with this, a recent astrocyte transcriptome analysis in the EAE model
reveals a down-regulation of GluA4 in spinal cord astrocytes [122]. The consequence of this alteration
in AMPAR expression are unclear. However, given the involvement of GluA4 in mediating Ca2+ influx,
and the influence of astrocytes on myelin formation and viability [91], it is interesting to consider the
detrimental effects that could arise due to an uncoupling of the axon-astrocytes interaction under
inflammatory excitotoxic conditions. Although not direct implicating AMPAR activation, astrocytic
GluA2 has also been linked to the pathogenesis of EAE. Recent work studying protein complexes
containing GluA2 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a key enzyme involved
in glycolytic metabolism, have identified an increase in the presence of this complex in EAE lesions [123]
(Figure 1B). This is significant since excitotoxic stimulation of AMPAR induces cell death in cultured
neurons via nuclear translocation of GluA2-GAPDH complexes, where it likely promotes cell death
via upregulation of the p53 pathway [124,125]. Interestingly, a cell penetrating peptide designed to
disrupt the formation of GluA2-GAPDH complexes ameliorates both clinical disease and the degree of
astrocyte reactivity in EAE [123]. In addition, the peptide reduces inflammation-associated changes in
isolated cultures of astrocytes, including increased expression of GFAP and EAAT1/2 proteins, nuclear
translocation of GluR2-GAPDH, and p53 activation [126]. These findings highlight AMPAR-mediated
GluA2-GAPDH nuclear translocation and p53 activation as a potential mechanism connecting glial
AMPAR to inflammatory excitotoxic disease states. Importantly, GluA2-GAPDH complexes are also
enriched in MS lesions [123] suggesting that this complex may represent a promising therapeutic
for inflammatory demyelination. In conclusion, while evidence linking astrocyte AMPAR activation
to CNS disease is limited, subtle changes in the molecular characteristics of astrocytes following
pathological AMPAR activation may contribute to the initiation and propagation of CNS injury
and disease. In addition, AMPAR subunits may stimulate inflammatory disease processes through
participation in novel protein complexes. Consequently, further work is required to investigate the links
between CNS disease states, disturbances in the astrocyte AMPAR transcriptome, and the intracellular
behaviour of GluA proteins.
3. Oligodendrocytes
Discovered by Pio Hortega in 1921, OL are the myelinating cells of the CNS [127]. Along development,
three different waves of OL generation have been identified in rodent forebrain: the first one, arising
from OL progenitors (OPC) stemming from the medial ganglionic eminence and anterior entopeduncular
area, happens around E12.5, and is almost completely replaced by early postnatal stages [128]. This wave
is followed by a second that originates in the lateral and caudal ganglionic eminences around day
E16.5 [128]. Finally, around birth a new wave of OPC with a cortical origin populates cortical areas [128];
although some studies have pointed out that this cortical oligodendrogenesis may occur earlier in
development [129]. Concerning cerebellar OL, their origin is mainly extracerebellar and with a likely
source being OPC from the ventral rhombomere 1 (r1) that populate the cerebellum by day E18.5 [130].
Two different waves of OPC have also been described in the spinal cord [131,132]. The first one around
E13, that produce most of the spinal cord OL, and the second, starting on E15.5, which contributes
a smaller population of OL in spinal cord [131,132].
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The maturation of the OL lineage is commonly divided into four stages: OPC, late OPC (also known
as preoligodendrocytes, preOL), immature OL (iOL) and mature myelinating OL (mOL) [133–135].
OPCs are characterized by a bipolar morphology and the expression of markers like PDGF-Receptor
α and NG2 [136,137]. These cells are able to migrate to different regions after damage or during
development [138,139]. Of note, OPC remain abundant in the adult CNS where they retain the
potential to differentiate into myelinating OL [15]. However, a substantial number of these cells remain
undifferentiated, and it is this fact, coupled with their unique physiological connection to neural
circuitry (see Section 3.2), that has led to the suggestion that they represent a distinct cell type, termed
‘NG2-glia’, with functions that extend beyond the generation of myelin forming cells [15,140,141]. Upon
arrival at their target sites developmental OPC remain mitotically active, elaborate their processes,
and lose their migrative properties before differentiating into preOL displaying immunoreactivity
to the O4 monoclonal antibody [136,142]. A further stage of differentiation sees preOLs transition
into iOL, which are post-mitotic cells with a highly complex morphological structure characterized
by expression of galactocerebrosidase (Galc, recognized by the O1 monoclonal antibody) [142–144].
Finally, these cells wrap the axon, myelinating it as mOL [145,146].
Traditionally, the main function OL has been to myelinate the axon. Myelination is associated
with an improvement of action potential transmission, increasing its speed and saving energy [147].
Thus, a lower velocity of conduction has been observed after demyelination [148], or in unmyelinated
axons [149]. A recent hypothesis has proposed that myelination could contribute to a type of brain
plasticity. Here, activity-dependent modulation of myelination on the most active fibers could,
by altering their conduction velocities, provide a mechanism for coordinating the flow of information
through neural circuits [10,150,151]. Myelin also protects axons from outside metabolites that could be
harmful [152,153]. Besides isolating the axon, myelin also plays a role in the energetic metabolism of
the axon as reviewed elsewhere [9]. These metabolic functions include involve the provision of energy
substrates such as lactate or pyruvate, whose delivery to the axon contribute to the preservation of
axon function and neuron survival [153].
3.1. Expression and Functional Properties of AMPAR in Oligodendrocytes
AMPAR are expressed at all stages of the OL lineage. OPC express all four GluA subunits,
although GluA1 appears to be less prominent [154–158]. Analysis by patch-clamp recording from OPC in
primary culture and acute brain slices indicate that OPC AMPAR exhibit rapid desensitisation kinetics,
and a degree of Ca2+ permeability [155,156,159,160]. In support of this electrophysiological evidence,
a number of Ca2+ imaging studies of OPC in cell culture and ex vivo preparations have revealed AMPAR
mediated Ca2+ influx [140,155,161]. Given the prominence of GluA2 in OPC [155], and evidence showing
the dominance of the Ca2+ impermeable Q/R edited form of GluA2 in hippocampal OPC [157] it has been
proposed that OPC exhibit both Ca2+ permeable (GluA2 lacking) and impermeable (containing GluA2)
AMPAR simultaneously [141]. A shift in potentiation to CTZ has been observed between postnatal
day 5 and 12 suggesting a developmental increase in the proportion of AMPAR containing the Flip
isoform [162]. Both Flip and Flop variants have been detected in the CG-4 OL cell line [163], but the
relative expression of these variants in OPC in situ has not to our knowledge been reported.
Differentiated OL (iOL/mOL) continue to express GluA mRNA and protein, although the
combination of subunits present appears to differ from that observed in OPC. RNA sequencing of
OPC, iOL (also known as newly formed OL) and mOL indicates that all four GluA transcipts are
down-regulated upon differentiation to the iOL stage, although the decline in GluA2 and GluA4
is less marked compared to GluA3 [164]. The decrease in expression continues with the transition
to the mOL stage, although as discussed below it is notable that levels of GluA4 transcript remain
relatively sustained [164]. In agreement with sustained GluA4 expression, AMPA receptor activation
induces intracellular Ca2+ influx in mature OL isolated from the optic nerve and cortex [65,155]. At the
protein level GluA2, 3 and 4 are detected in cultured iOL and mOL [155], and immunocytochemical
staining has revealed expression of GluA4 in the soma and myelin of spinal cord OL [106], and in the
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soma and processes of CNPase-GFP expressing OL in optic nerve [165]. In the latter study, GluA2
was not detected in OL, but GluA3 protein expression in OL soma was inferred using anti-GluA2/3.
In addition, a recent study in human white matter detected localisation of GluA4 protein to MBP+
myelin sheaths [166,167]. In contrast to these data, OL lineage cells within the forebrain white matter of
immature rats exhibit immunoreactivity for GluA1, 2 and 3, and a brief expression of GluA4 protein on
04+ lateOPC between postnatal days 7-9, which was not observed on GalC+ iOL [168]. The expression
and functional properties of OL lineage AMPAR are summarised in Table 2.
Table 2. Summary of AMPAR expression and functions in oligodendrocytes.
Preparation GluA Expression Ca
2+ Permeability Functions
Degree Evidence Physiological Pathophysiological
OPC in vitro GluA2, 3, 4 (qPCR,WB) [154,155] ++
Ci [155,169]
ePhys [155] IEG expression [44]
Excitotoxicity [170]
OGD injury
[171–173]
NF-Y-dependent
apoptosis [45]
OPC ex vivo N.D. + Ci, ePhys [161]
Proliferation,
Differentiation [41,43]
Migration [39]
Blockade of K+
currents [43,174]
OPC LTP [175]
OGD injury [165]
OPC in vivo GluA2-4 (FISH) [46] N.D. N.D. Survival [165]
H-I injury [172]
Remyelination
[148,176]
OL in vitro GluA2, 3, 4 (qPCR,WB) [155] +
Ci [155,177]
ePhys [155] N.D. Excitotoxicity [65]
OL ex vivo GluA4 (IHC) [106] + Ci [109] Activate NMDAR [109] Excitotoxicity [106]
OL in vivo GluA2/3 (IHC) [177]GluA4 IHC [167] N.D. N.D. N.D.
Demyelination [119]
H-I injury [178]
Spinal cord injury
[179]
+ intermediate Ca2+ permeability; ++ high Ca2+ permeability Cb: cerebellum; Ci: calcium imaging analysis; ePhys:
electrophysiological analysis; IEG: immediate early gene; IHC: immunohistochemistry; H-I: hypoxic ischemia; FISH:
fluorescent in situ hybridization; N.D.: not determined; OGD: oxygen glucose deprivation; qPCR: quantitative
real-time PCR; WB: Western blot.
3.2. Oligodendrocyte AMPAR Functions Under Physiological Conditions
It is tempting to hypothesize that the pronounced alterations of AMPAR expression observed during
OL differentiation [155,164] are related with the receptors role in OL maturation and myelination. Indeed,
in line with evidence from other neural cell types, AMPAR have been implicated in developmental OL
maturation and myelination [39,41,43,46,180] (Figure 1). AMPAR activation seems to have an inhibitory
effect on OPC proliferation. This is observed by the reduction of the proliferative ratio after AMPAR
stimulation in cell cultures [42], as well as its increase after AMPAR antagonism in organotypic cerebellar
slice [41,43]. In agreement with this, a promotion of OPC proliferation has been studied after suppressing
axonal release of glutamate [148]. By contrast, AMPAR activation appears to play a role in the recruitment
of OPCs to target axons [148], perhaps via effects on OPC migration speed [37]. AMPAR also play a key
role in OL differentiation, promoting the elongation and branching of OPC processes [41]. Indeed, this
receptor seems to participate in the early stages of OPC lineage maturation rather than in developmental
myelination [46,148], with alterations of this receptors inducing delays of myelination by reducing the
number of mature oligodendrocytes [46].
The involvement of OPC AMPAR in developmental myelination has been challenged by recent
in vivo work involving mice carrying a conditional deletion of OPC GluA2, 3, and 4 [46]. OPC AMPAR
currents are completely abolished under these conditions, yet analysis of OPC in tissues from these mice
failed to detect a change in OPC proliferation or differentiation [46]. Instead, the genetic ablation of OPC
AMPAR resulted in a decrease in OPC survival. Importantly, parameters of myelination considered to be
Int. J. Mol. Sci. 2019, 20, 2450 13 of 39
senstive to neuronal acitvity such as internodal length [181] and number [182] also remained unaltered.
These findings are in contrast with data from larval zebrafish and rodent optic nerve where suppression
of neuronal activity and attenuation of vesicular glutamate induce a measurable decrease in internode
number and length respectively [182,183]. Technical differences in the approaches used to modulate
glutamatergic actions on OPC could account for these contrasting results. Kougioumtzidou et al. [46]
used a non-inducible Cre strategy to delete Gria2 and Gria4 in OPC on a constitute Gria3−/− background.
These tripple transgenic OPC lacked functional AMPAR through development, thus they would have
been insensitive to all sources of glutamate-mediated AMPAR stimulation, be that vesicular or otherwise.
One consideration is whether complete starvation of AMPAR-mediated signaling through the life-span
may induce compensatory changes in OPC that mask the function of AMPAR in OPC maturation and
myelination. In support of this view, recent work using OPC-specific retroviral-mediated modulations
that alter OPC AMPAR only during postnatal development have identified an involvement of these
receptors in OPC proliferation and differentiation, but not survival [180] (discussed in more detail
below). With regard to the study by Kougioumtzidou et al. [46], it should also be noted that Gria2, 3,
and 4 lacking OPC would continue to receive glutamatergic stimulation from NMDAR [165,184,185],
thus actvitity-dependent glutamate signaling could still influence OL maturation and myelination [185]
(but see [186]). In contrast, Mensch et al. [183] and Etxeberria et al. [182] targeted glutamate release,
rather than AMPAR expression, thus OPC in these studies could continute to receive stimulation from
glutamate released by non-vesicular sources, which may act on both AMPAR and NMDAR. The use of
an inducible-conditional Gria 2, 3, 4 deletion, perhaps via a multiplex CRISPR-based knockout strategy,
could help to bring further clarity to the role of AMPAR signaling in OPC maturation and myelination.
Notably, OPC AMPAR are activated by vesicular release of glutamate from unmyelinated axons in
white and grey matter [141,187–189] (Figures 1A and 2A). The function of these neuro-glial synapses is
unknown, but it is hypothesised that they may signal levels of activity within neural circuits, perhaps
allowing OPC to regulate their proliferation or differentiation at sites of increased activity [141,190].
In agreement with this idea, AMPAR-mediated input declines upon differentiation of OPC [191], and
synaptic activity can induce Ca2+ influx into OPC via AMPAR [159,160], thus the synaptic activation of
pro-differentiation Ca2+-dependent intracellular signals seems a possibility. However, recent evidence
suggests a role for axon-OPC synapses in regulating proliferation but not differentiation [180]. In this
work increases in the Ca2+ permeability of OPC AMPR via OPC specific expression of either non
Q/R edited GluA2 subunits, or a “pore dead” GluA2 construct, promoted OPC proliferation without
affecting differentiation or survival. Thus neuronal activity may influence OPC proliferation via the
activation of OPC AMPAR and the subsequent activation of Ca2+-dependent signaling pathways.
Interestingly, an additional strategy that reduced the proportion of Ca2+ permeable AMPAR in OPC
without affecting GluA2 channel properties caused an increase in the size of the OPC population
without altering proliferation or survival [180] suggesting further complexities in the influence of
AMPAR on OPC development. Contrasts between these findings, and those indicating an enhancement
of OPC proliferation following AMPAR antagonism in cerebellar slice cultures [41,43] may be explained
if bath applied AMPAR blockers, as used on ex vivo slices, affect additional mechanisms that impinge
on OPC functions. One possibility, as highlighted previously [41], would be an effect on neuronal
synapses whose inhibition would be expected to produce similar effects to that seen when neuronal
activity is blocked pharmacologically. Of note, both TTX and the AMPAR antagonist GYKI induce
a similar stimulation of OPC proliferation in cerebellar slice cultures [41]. Taken together there is
considerable evidence that OPC AMPAR, including those recruited via neuron-OPC synapses, exert
influences on OPC migration, proliferation and survival during CNS development (Figure 1A).
Interestingly, a large numbers of OPC, or NG2-glia, persist in the adult CNS where they continue to
receive synaptic input from neuronal circuits [reviewed by 182]. These NG2+ cells seem able to respond
to this activity since, like their developmental counterparts [161], they exhibit activity-dependent and
neurotransmitter receptor dependent Ca2+ transients [192]. These observations, and morphological
data showing that their processes make intimate contact with multiple neuronal and astrocyte elements,
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are suggestive of specialized functions within the CNS [192]. Indeed, it has been proposed that NG2+
cells might regulate glutamatergic synapses by modulating postsynaptic AMPA [193], although this
idea remains controversial at this time [194]. Aside from a role in remyelination (Section 3.2) other
functions for OPC/NG2-glia in the adult CNS remains an open question.
Regarding differentiated OL, both iOL and mOL continue to express AMPAR (Section 3.1), and
GluA4 has been detected in rodent spinal cord myelin [106] and human cortical white matter [167].
Ca2+-permeable AMPAR containing GluA4 may contribute to activity-dependent signaling between
axons and myelin. Electrical stimulation of an ex vivo optic nerve preparation induces Ca2+ signaling
in myelin that is blocked by NMDAR and AMPAR antagonists [109]. These data suggest that AMPAR
activation may provide a depolarizing stimuli that relieves Mg2+ blockade from NMDAR, and indeed
imaging in zero Mg2+ revealed a subtle NDMAR-dependent elevation in Ca2+ [109]. This form of
activity-dependent signaling involves vesicular release of glutamate: Ca2+ signals were blocked by
bafilomycin and tetanus toxin, both of which disrupt vesicular release; and enhanced by hypertonic
sucrose stimulation, which encourages vesicle release. Whether or not this form of axon-myelin
signaling occurs in other regions of the CNS, and what function it may play in regulating axon-OL
interactions remains unclear. However, it has been proposed that an ‘axo-myelinic’ synapse may enable
mOL to sense activity in target axons, allowing them to adjust the provision of metabolic support [195],
perhaps via the provision of lactate [196], or to fine tune myelin internode parameters such as length
and thickness in response to changes in demand [195].
3.3. Oligodendrocyte AMPAR in Pathology
The prominent expression of Ca2+ permeable AMPAR in the OL lineage places these cells at
threat of injury from excitotoxic conditions (Figure 2B). Indeed, AMPAR-mediated excitotoxicity
has been described in numerous in vitro studies using cultures of both OPC/preOL [45,170,171]
and differentiated OL [65,163,197]. Importantly, excitotoxicity in these cells is associated with
excessive Ca2+ influx [65,171], thus expression of Ca2+ permeable AMPAR, as described in Section 2.2,
appears to render these cells vulnerable to high levels of extracellular glutamate. In support of
this idea, specific antagonists of Ca2+ permeable AMPAR reduce injury in OL subjected to oxygen
glucose deprivation [171], while forced expression of Q/R edited GluA2 subunits protected OPC from
an AMPAR-induced excitotoxic injury [173]. Given the links between Ca2+ influx and cellular injury
responses in OPC, the degree of Ca2+ permeable AMPAR expression in OPC would be expected to
regulate vulnerability to excitotoxic injury. In this respect, it is interesting that group 1 mGluR activation
leads to an increased surface expression of Ca2+ permeable AMPAR in OPC [198]. This mechanism,
which involves specific TARP-dependent trafficking of the Ca2+ permeable GluA4 subunit, may act to
amplify the sensitivity of OPC to elevated levels of extracellular glutamate. However, at this time the
links between mGluR activation and OPC excitotoxicity remain unclear.
AMPAR-mediated injury has been observed in a number of in vivo models involving OL and myelin
injury. For example, the AMPA antagonists NBQX reduces OL and myelin loss in rats subjected to
a weight-drop spinal cord contusion injury [179], and as discussed below, ameliorates inflammatory
demyelination in the EAE model of MS [119,120]. These observations are significant since excitotoxicity is
implicated in a number of pathologies (described in Section 1.3) including Cerebral White Matter Injury
(WMI) and MS [199,200]. In premature infants WMI includes different neuropathological cerebral white
matter [201], the survivors of which eventually develop long-term neurological disabilities [199,202]. Within
the framework of pre-term conditions, H-I damage has been specifically correlated to oligodendrocyte
maturation, with preOL being identified as being particularly vulnerable in several species [115,203–205]
including human [206]. For a detailed discussion of perinatal WMI see the recent review by Back et al. [199].
Importantly, within the OL lineage, preOL in developing white matter exhibit the greatest abundance of
GluA4 [168,207], a Ca2+ permeable subunit highly expressed in neural cells exhibiting vulnerability to
excitotoxic death [208]. Importantly, topiramate and NBQX reduce OL death in rodent models of neonatal
H-I injury [172,178]. Thus, the protection of OL via the targeting of Ca2+ permeable AMPAR, or relevant
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downstream pathways, represents a potential strategy for the prevention of WMI in pre-term infants.
However, despite these promising pre-clnical findings, it should be noted that other pathogenic events are
likely to be relevant since preOLs are also very sensitive to increased levels of TNFα and oxidative stress,
both of which are characteristic of WMI [209–211].
Related results are obtained after stroke in neonatal and adult rodent models. In both cases, cerebral
ischemia is followed by a decrease in the mOL population [212,213] as well as OPC proliferation and
migration into the damage areas [213,214]. mOL death is reproduced in vitro by AMPA but not NMDA
administration, and is reduced by AMPAR antagonist after oxygen and glucose deprivation [197,215].
The administration of AMPAR competitive antagonist, SPD 502, mimics this oligoprotection after
cerebral stroke induced in adult rats [216]. Interestingly, this effect is regionally restricted since the
oligoprotection is specific to cortical OL. As mentioned above, brain OL are heterogenous both in
respect of their developmental origins, and their differentiation rates in grey and white matter [217,218].
Therefore, deeper studies to analyze how AMPAR modulation affects specific OL populations are
warranted if AMPAR-targeting therapeutics are to be developed further.
A number of observations link glutamate dysregulation and OL AMPAR to pathology in MS. First,
MS is characterized by high levels of glutamate within CSF [5,62]. Second, an increase in levels of the
Ca2+ permeable subunit GluA1, but not GluA2, in oligodendrocytes located next to MS plaques has been
observed in post-mortem CNS samples of MS patients [219]. Third, a greater level of GluR2–GAPDH
complexes are detected in MS plaques [123], and disruption of the GluA2-GAPDH complex has been
shown to produce a therapeutic/protective action in EAE [123] (see Section 2.3 for a related discussion
on this topic). Fourth, Ca2+ permeable AMPAR are implicated in CNS pathology in EAE where OL
death, axonal damage and demyelination are reduced in mice lacking Gria3, the gene encoding the
Ca2+ permeable GluA3 subunit [220]. In agreement with these latter findings, other work in the EAE
model encourages the use of AMPAR as therapeutic targets in MS since blockade of these receptors via
subcutaneous injection of NBQX reduces clinical disease and protects OL [119,120]. These promising
preclinical results from models of MS [221], and also stroke [216,222], must be weighed against the
negative findings from clinical studies that have observed worsened outcomes following the use of
AMPAR-targeting drugs in patients with acute ischemic stroke, [223,224]. These disappointing results
may be explained by the low specificity of the drug used, ZK200775, and the wide expression of these
receptors in CNS circuitry, where their inhibition may be expected to produce numerous unwanted side
effects that may interfere with any potential therapeutic benefits. As discussed above (Section 3.2) AMPAR
influence the development and survival of OL. Consequently, protection of OL from excitotoxic conditions
associated with CNS inflammation may not be achieved without compromising the regenerative capacity
of OPC (but see [172]). Nonetheless, glutamate dysregulation plays wider roles in MS pathogenesis via
actions on T cell function such as migration and cytokine secretion, and even glutamate release [5], thus
therapies focused on controlling glutamate levels may provide significant benefits that extend beyond
oligodendrocyte protection.
The activation of OPC AMPAR by axonal synaptic input may play a role in regulating
OPC-mediated remyelination (Figure 1). New OPC recruited to lesions express AMPAR, which may be
involved in both migration and the early stages of myelination [39,148]. Within the caudal cerebellar
peduncle, axons demyelinated by infusion of ethidium bromide establish de novo glutamatergic
synapses with recruited OPCs, while infusion of antagonists of specific voltage-gated Ca2+ channels,
selected to specifically act on axonal channels, reduce the degree of remyelination [148,176]. Thus,
synaptic activation of OPC AMPAR appears to be important for remyelination. Another study tracked
the occurrence of synaptic inputs on OPC following lysolecithin lesions in the corpus callosum [176].
Here the authors report a disruption of synaptic input shortly after demyelination that correlates with
a reduction in immunohistologically identified axonal synaptic connections on proliferating OPC in the
lesion. Interestingly, a recovery in synaptic innervation coincides with a reduction in OPC proliferation,
suggesting that AMPAR activation may inhibit cell division [176]. This observation agrees with recent
studies indicating a role for synaptic Ca2+ permeable AMPAR in stimulating OPC proliferation [180],
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and with data from brain slice cultures and in vivo studies that show that blockade of axonal activity
increases OPC proliferation [41,148,225,226]. However, blockade of activity in ex vivo brain slices
also produces an increae in OL differentiation [41] that was not observed under in vivo remyelinating
conditions [148]. These contrasting outcomes may be explained by differences in experimental models
(ex vivo vs. in vivo) and the developmental status of the tissues examined (developing white vs adult
remyelinating). Despite these differences the data from these studies, and many others from a variety
of different CNS systems, clearly indicate an important role for axonal activity and AMPAR in the
regulation of OL myelination [113,181–183,225,227] (Figure 1).
In conclusion, the excessive activation of OL AMPAR poses numerous threats to the viability of
OL and the myelin they support. This loss of myelin compromises neurological function in a wide
range of CNS disease states, thus therapies that protect OL from excitotoxic AMPAR-mediated injury
are an important clinical goal. Nevertheless, AMPAR are powerful regulators of OL development and
survival, and may also play unidentified functions in adult-NG2-glia. Therefore, AMPAR-targeting
therapies capable of protection OL may induce unwanted side effects, and potentially hinder other
aspects of OL regeneration and myelin repair. Further basic and pre-clinical research will be necessary
to fully identify the functions of OL AMPAR, and determine the benefits and feasibility of targeting
these receptors in a therapeutic context.
4. Microglia
Microglia are highly abundant CNS glia, whose origin within the embryonic yolk sac [6], and
macrophage-like functions, distinguish them from all other parenchymal glia in the nervous system.
In the healthy brain microglia exhibit highly motile processes that scan the local tissue landscape,
seemingly searching for signs of disease or injury whose detection may trigger them into acquiring
an activated amoeboid phenotype capable of launching inflammatory responses and engaging in
phagocytic activity [228]. Microglia are considered to serve a number of protective roles that collectively
help to maintain a healthy environment with the CNS. These functions include the removal of dead and
dying cells, the regulation of synapse number via pruning of excess connections, and the production
of various neurotrophic factors capable of influencing the development and survival of other neural
cells [22]. In addition, microglia express major histocompatibility complex (MHC) I and II molecules,
particularly under pathological conditions including perinatal hypoxia, thus a role in the detection
of pathological conditions and the stimulation of adaptive immune responses are ascribed to these
cells [229]. In addition to protecting the healthy CNS, microglia contribute to the generation of
pathological conditions via the synthesis and release of cytotoxic molecules such as nitric oxide, reactive
oxygen species and proinflammatory cytokines [230]. They also contribute to CNS repair processes by
releasing neuroprotective factors, reducing inflammation, and encouraging regenerative processes
such as OPC differentiation and remyelination [230]. These contrasting roles in CNS protection and
injury have frequently been cast within a model where microglia exhibit polarised states, the so-called
M1 (pro-inflammatory)/M2 (anti-inflammatory pro-repair) phenotypes [231]. However, a number of
observations, such as the co-existence of cardinal M1/M2 molecules within microglia in vivo, have lead
this dichotomy to be described as unsuitable and unhelpful for the understanding of microglial biology
within the intact CNS [232]. Nevertheless, microglia certainly exert profound and varied influences in
the context of CNS protection, immune activation, injury and repair, whose regulation by AMPAR may
contribute to the induction and progression of a number of disease states.
4.1. Expression and Functional Properties of AMPAR in Microglia
Consistent evidence for function AMPAR expression in microglia has been reported in experiments
on cultures of cortical rat microglia [233]. Reverse transcription PCR indicates that these cells express
GluA transcripts 2, 3 and 4 [234], although a subsequent study using more sensitive quantitative
RT-PCR method detected GluA, 1, 2 and 3 mRNA [235]. Expression of GluA1 has also been shown
at the protein level in rat cortical microglia via immunocytochemistry [236]. Functionality for these
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AMPAR has been confirmed by patch-clamp analysis where CNQX sensitive glutamate currents are
detected [233]. These currents were potentiated by CTZ, and showed little Ca2+ permeability [233],
consistent with the presence of GluA2 transcripts. Interestingly, experiments with AMPAR modulators
show that microglial glutamate currents exhibit a greater degree of potentiation to CTZ compared to
PEPA [234]. CTZ is selective for Flip variants, while PEPA exhibits a greater affinity for Flop subunits,
thus these data suggest a dominance of Flip splice variants in microglia [234]. In line with this finding
transcript analysis in the same study revealed a predominance of GluA1-3 Flip variants, a configuration
that may render cells more sensitive to excessive glutamate levels (Section 1.2). In contrast to the
in vitro studies described above, evidence for microglial AMPAR expression in vivo is more uncertain.
AMPAR expression has been detected by immunostaining for GluA2/3 and 4 in OX-42 cells in rat
forebrain sections [237], although this work was done under permeabalising conditions hence it is not
clear if the immunosignals represent surface expressed receptors. Importantly, immunostaining did
not identify receptor subunits on the surface of retinal microglia, and patch-clamp recordings from
microglia have failed to detect glutamate-mediated currents in a range of CNS tissues including spinal
cord, hippocampus and retina (reviewed in [238]). Interestingly, hypoxia causes a marked increase
in microglial GluA2-4 protein expression within forebrain periventricular white matter [237], and
hippocampal microglia express GluA4 protein only after exposure to an ischemic injury [239]. These
in situ observations suggest that microglial AMPAR expression may be low or absent under healthy
conditions, but may be induced in microglia activated under pathological conditions [238] (Figure 2).
Furthermore, the contrast between these findings, and those from in vitro studies, suggest that the
physiological properties of microglia may differ significantly under cell culture conditions. Indeed,
differences in the expression of voltage-gated K+ channels are observed when patch-clamp recordings
are made from microglia in actute vs cultured hippocampal brain slices [240]. A summary of findings
on the expression and functional properties of microglial AMPAR are summarised in Table 3.
Table 3. Summary of AMPAR expression and functions in microglia.
Preparation GluA Expression Ca
2+ Permeability Functions
Degree Evidence Physiological Pathophysiological
In vitro
GluA2,3,4 (RT-PCR) [233]
GluA1,2,3 (qPCR) [234]
GluA1 (ICC) [236]
- ePhys [225,226] Chemotaxis [117]
Hypoxia induced
increase in GluA2-4 [237]
Release of IL-1b and
TNF-a [234,237]
TNF-a release [234]
In vivo GluA2/3, 4 (IHC) [237]No AMPAR (ePhys) [238] No AMPAR ePhys [238] N.D.
Hypoxia/Ischemia
increased GluA2-4
[237,239]
–: negligible Ca2+ permeability; ePhys: electrophysiological analysis; ICC: immunocytochemistry; IHC:
immunohistochemistry; qPCR: quantitative real-time PCR; RT-PCR: reverse transcription PCR; N.D.: not determined.
4.2. Microglial AMPAR in Pathology
Evidence linking AMPAR activation to microglial functions under physiological conditions
appear to be limited to effects on chemotaxis, where glutamate stimulates a directed-migration
of microglia in cell cultures and spinal cord slices via AMPAR receptors [117]. In contrast, several
interesting actions are associated with the activation of microglial AMPAR under pathological conditions
that are linked with excessive glutamate signaling. Studies using a rat model of periventricular
white matter (PWM) injury, and microglial cell cultures exposed to hypoxia, have identified links
between hypoxia-induced elevations in glutamate, and the regulation of protective and inflammatory
microglial-derived substances [237] (Figure 2B). This work shows that hypoxia causes increases in
PWM concentrations for both glutamate and IGF-1, a neurotrophic factor associated with the protection
of neurons [241] and oligodendrocytes [169,170] following H-I injury. Importantly, elevated IGF-1
protein is localised to microglial with an activated amoeboid morphology that also exhibit enhanced
expression of GluA2, 3 and 4 subunits [237] (Figure 1B). While increased expression of IGF-1 may
Int. J. Mol. Sci. 2019, 20, 2450 18 of 39
play a protective role following this injury, the increase in AMPAR expression in these cells appears to
prime them for a more pathological response since a subsequent exposure to glutamate simultaneously
attenuates IGF-1 production, while promoting TNF-α release and IL1-beta [237]. This inflammatory
response is mechanistically linked to the reduced levels of IGF-1 seen after glutamate stimulation
since knock-down of IGF-1 gene expression promotes TNF- α and IL-1 beta gene expression. Overall,
the study by Sivakumar et al. [237] suggests that increased expression of microglial AMPAR in hypoxic
PWM tissue sensitises microglia to glutamate leading to a regulatory response that reduces protective
IGF-1 release while increasing the release of inflammatory mediators.
Other evidence suggests that microglial AMPAR activation, and a subsequent production and release
of TNF-α, may contribute to the propagation of CNS disease states (Figure 2B). First, cell culture and
in vivo experiments show that the activation of microglia AMPAR stimulates the production and release of
TNF-α [234,237]. Second, TNF-α signaling is heavily associated with a number of glial-dependent actions,
including the emission of glutamate via gap-junction hemichannels from microglia [242] and astrocytes,
Fas ligand release from microglia, and the downregulation of EAAT2/GLT1 glutamate transporters in
astrocytes, which trigger neurotoxicity in the CNS [2]. Third, TNF-α release from astrocytes stimulates the
trafficking of AMPAR to the surface of hippocampal and cortical neurons, rendering them more sensitive
to excitotoxic conditions involving excessive levels of extra cellular glutamate [243]. Fourth, conditioned
medium containing TNF-α released from kainate-stimulated microglia induces the upregulation of
voltage-gated Ca2+ channels and NMDA-type glutamate receptors in hippocampal neurons, and is
associated with neuronal apoptosis [244]. In summary, microglial AMPAR-mediated TNF-α release,
acting through a range of autocrine and paracrine routes, are positioned to elevate extracellular glutamate
concentrations, release apoptosis inducing signals, and increase the sensitivity of neurons to excitotoxicity.
As outlined in Section 1.3, excitotoxic injury has a link to a wide range of CNS injury and disease
states [1,4], thus further investigation of the influence of the microglial AMPAR-TNF-α axis, and its
actions in propagating excitotoxic conditions, are warranted. In this regard, a promising area for research
can be found in the context of MS, where impaired cognitive function may be linked to pathological
alterations in synaptic structures that arise early in the course of the disease [245]. Research using the
EAE model of inflammatory demyelination shows that TNF-α contribute to the mechanisms driving
these synaptic dysfunctions, at least within the striatum, where these pathophysiological actions are
correlated with the activation of microglia and astrocytes [246,247]. While the involvement of microglial
AMPAR is in these actions is unknown, the established links between their activation and the release
of TNF-α [234,237] indicates that they could be capable of amplifying an initial inflammation-induced
elevation in extracellular glutamate into additional excitotoxic insults.
Microglial AMPAR have also been implicated in neurodegenerative disease processes through
a series of cell culture studies examining the regulation of GluA subunit surface expression in activated
microglia [248]. Here, the authors examined the hypothesis that down-regulation of GluA2, as is
observed in a number of neurodegenerative conditions including MS [249], drives neurotoxicity
via increased release of pro-inflammatory cytokines from microglia. Analysis of cultured microglia
generated from a global GluA2 null line exhibited a greater degree of Ca2+ permeability, and enhanced
TNF-α production following AMPAR activation. In line with this data, conditioned medium from
GluA2 -/- microglia exerted a greater neurotoxic effect on cultured neurons. Thus, as proposed by Noda
and Beppu [250], the loss of microglial GluA2 under pathological conditions may serve to accelerate
neuronal injury and loss via alterations in the subunit composition of their AMPAR that favour Ca2+
entry and inflammatory cytokine release. While this hypothesis provides an attractive link between
microglial AMPAR function and disease, further work should be performed using a conditional
deletion of GluA2 in microglia to refine the loci of action and confirm the relevance of this mechanism
in relevant in vivo disease models.
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Table 4. Summary of AMPAR expression and functions in other glia.
Tissue Age GluA Expression Ca
2+ Permeability Functions
Degree Evidence Physiological Pathophysiological
RG Developing
Tissue
GluA1, 2, 3 (qPCR, ICC) [251]
GluA3, 4 (qPCR) [252]
GluA3,4 [252]
+ Ci [251] N.D. N.D.
RG Adult tissue GluA2, 3 and 4 (qPCR) [166] N.D. N.D. Proliferation,survival [253] N.D.
Tanycte GluA2/3 (IHC) [254] N.D. N.D. N.D. N.D.
Schwann cell
GluA2/3, 4 (IHC, I-EM) [255]
Functional AMPAR in
developing cells [256]
+ ePhys [256,257] ATP release [258] N.D.
Satellite glia GluA4 (IHC) [259,260] + Ci [259,260] N.D. N.D.
Enteric glia GluA1, 3 (qPCR, WB) [261] N.D. N.D. N.D. N.D.
+: intermediate Ca2+ permeability; ePhys: electrophysiological analysis; ICC: immunocytochemistry; I-EM:
immunogold electron microscopy; IHC: immunohistochemistry; qPCR: quantitative real-time PCR; RG: Radial Glia;
N.D.: not determined; Western blot: WB.
In summary, microglial are equipped with AMPAR whose activation may help to synchronise
the production and release of inflammatory molecules to inflammatory excitotoxic conditions within
the tissue. These actions could trigger de novo excitotoxicity or may contribute to the propagation
of an ongoing disease state. Based on these actions, therapies targeting microglial AMPAR represent
a valuable ambition, the achievement of which may provide a means to modulate neurotoxicity in
a number of neurodegenerative CNS conditions.
5. AMPAR in Other Glial Cells
AMPAR are expressed in glial cells beyond the principle types described in Sections 2–4, yet their
functions in these ‘other glia’ are less characterized. Nonetheless, these glia, which in this review include
Radial Glia, Schwann Cells, Satellite Glia and Enteric Glia, have important functions in both CNS and
PNS. Therefore, AMPAR might yet play significant roles in their behavior under physiological and
pathophysiological conditions. Here we present a brief overview of AMPAR in these other glial cells.
See Table 4 for a summary of the expression and functional properties of AMPAR in these glial cells.
5.1. Radial Glia
Radial glia (RG) gives rise to astrocytes, neurons, and oligodendrocytes during embryonic
development [16,262,263]. In primary cell cultures of RG-like neural progenitor cells (NPC) qPCR
reveals a high level of GluA1 mRNA, and lower levels of GluA2, 3 and 4, while immunostaining
detects GluA1, 2 and 3 protein expression on RG/NPC expressing the glial marker GLAST [251].
The functionality of these AMPAR is evident in Ca2+ imaging data where transient AMPA induced
elevations in intracellular Ca2+ are enhacned by CTZ and reduced by philantotoxin, a specific antagonist
of Ca2+ permeable AMPAR [251]. In contrast, another study revealed high levels of GluA3 and 4 mRNA,
and an absence of GluA1 and 2, in NPC [252]. In agrement with this data, immunohistochemical
staining reveals strong GluA3 and 4 localisation to RG in the developing white matter of rodents [168],
while GluA4 is localised to RG in fetal human RG [207]. Differentiation of RG/NPC into astrocytes
or neurons involves an increase of GluA2 and a decrease of GluA3/4, thus suggesting an increase in
the proportion of Ca2+ impermeable AMPAR [168,207,252,253,264]. These findings suggests a role for
glutamate acting via AMPAR in RG proliferation and differentiation. In agreement with this idea,
AMPAR are involved in the regulation of RG processes length and RG motility [265].
RG-like cells are also present in the adult subgranular zone of the hippocampus [166,253].
In contrast to developmental RG, these adult RG-like cells possess AMPAR that are mainly composed
of GluA2 subunits, and which are expressed in the cell’s processes but not in the soma [166].
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The administration of kainate promotes RG-like cell proliferation and survival, both in vitro, and
in vivo, in an animal model of status epilepticus [253].
Very little is known about AMPAR expression in ependymal cells derived from radial glia, although
GluA2/3 expression has been found in cell bodies and proximal thick processes of tanycytes [254].
5.2. Schwann Cells
As mentioned in the introduction (Section 1.1), Schwann cells are the myelinating cells of the PNS.
As in the CNS, PNS axons extend significant distances, thus in addition to the benefits associated with
OL myelination, such as enhanced conduction velocity and axonal isolation (Section 3), trophic support
arising from myelinating Schwann cells is likely to be important for sustaining the viability of axons
located long distances from the cell body [152]. Distinct from the myelinating forms, the perisynaptic
Schwann cells (PSCs) are non-myelinating cells that are part of the neuromuscular junction (NMJ)
formed between the presynaptic nerve terminal and the postsynaptic specialization [264]. These cells
plays an important role in the growth and maintenance of NMJs as well as in the modulation of its
synaptic properties [264,266,267]. In comparison to OL, the very little less is known regarding the
expression and function of AMPAR in SCs.
During development mRNA expression of all AMPAR subunits is detected in mouse sciatic nerve,
although it is not clear if this expression arises from the axon or glial cells [256,268]. While GluA2/3
and GluA4 are detected by electron microscopy in Schwann cells of the vestibular system of rats and
guinea pigs; only GluA1 and GluA4, but no GluA2 or GluA3, protein expression are found in primary
SC culture [255,258]. Patch-clamp recording from developing SC in peripheral nerve tissue and cell
cultures exhibit functional Ca2+ permeable AMPAR [256,257]. A detailed study performed in sciatic
nerve preparation of mouse pups at embryonic day 16th–18th or postnatal day 0–2nd has proved that
AMPAR are modulated along development, with functional AMPAR only expressed in developing SCs
while more mature myelinating SCs are unresponsiveness to glutamate [256]. Furthermore, the amount
of AMPAR might also be modulated in developing SCs [256].
However, the AMPAR role in SCs is still not clear. Metabotropic glutamate receptors
activation induces SCs proliferation, whereas migration induced by glutamate are also NMDAR-
dependent [268–270]. AMPAR activation on PNS myelinated axons induced an increase of axoplasmic
Ca2+, although myelin abnormalities are only observed after prolonged activation of NMDA, but not
AMPAR [271]. AMPAR activation has also be found to control ATP release after glutamate stimulation in
SCs culture [258].
5.3. Satellite Glia
Among satellite Glia cells (SGCs), those of the sensory ganglia has been the most studied. [25].
SGCs are in close contact with neurons, ensheathing them and playing a role in neurotransmission
and glutamate homeostasis [25,259,260,272]. To that end, SGCs express several glutamate transporters,
metabotropic glutamate receptors, NMDAR, KR and AMPAR [259,260]. Regarding AMPAR, SGCs
express mainly GluA4 and in lesser quantities GluA2/3 but no GluA1 [259,273]. AMPAR activation
induces a rapid Ca2+ influx in SGCs inline with their expression of GluA4 [259]. In addition, a role
for SGC NMDAR has been described in pathological situations like hyperalgesia [274]. It is therefore
tempting to hypothesize that AMPAR could also play a role in SGCs response after damage.
5.4. Enteric Glia
Enteric glia are non-myelinating glial cells of the enteric nervous system, localized within the wall
of intestines they are critical in the control of gut motility [275,276]. Despite showing some similarities
to astrocytes, enteric glia display a unique transcription profile [275,276]. The connection between
enteric neurons and enteric glia is not well characterized, although ionotropic glutamate receptors
have been found in both cell types [261,275]. Concerning AMPAR only GluA1 and GluA3 subunits
have been found in enteric glia, but the Ca2+ permeability of the functional AMPAR has not been
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fully elucidated yet [261]. AMPAR are involved in excitotoxic damage to enteric neurons in studies
performed in myenteric ganglia [277,278]. Although it is unclear whether these pathological actions
involve AMPAR located on enteric glia, their expression of GluA proteins suggests they may also be
targets during ischemic injury in these enteric tissues.
6. Cannabinoids and AMPA Receptor
Several studies have pointed out that cannabinoids and the Endocannabinoid System (ECS)
might modulate glutamatergic transmission, including AMPAR. This modulation has been principally
studied in neurons, although glial receptor involvement has also been described [279–281].
The medical use of Cannabis sativa has been explored for millennia worldwide [282]. Modern
research in the cannabinoids field started during the last century with the isolation of ∆9-
tetrahydrocannabinol or THC [283], a discovery that eventually lead to the recognition of the ECS. The
ECS is an endogenous system that plays important physiological roles, modulating neuronal synapses,
the immune response or energy and metabolism regulation, among others [284–288].
As has been recently reviewed, the ECS modulates OL lineage cells and myelination [289]. Different
elements of the ECS are expressed in all OL stages, and observations that the ECS is modulated during
OL maturation, suggest that they may play a role in OL differentiation [290,291]. The endocannabinoid
2-arachidonoylglycerol (2-AG) and cannabinoid receptors CB1 and CB2 activation promote OPC
proliferation, migration and maturation, and oligodendrocyte myelination [290–295]. Indeed, different
pharmacological studies have proved that the reduction of 2-AG levels, or blocking either CB1 or CB2
reduces myelination, both in vitro and in vivo [291,296].
Based on the links between the ECS and OL lineage functions described above, the modulation
of the ECS has been studied as a possible treatment for demyelinating diseases like MS [289].
A cannabinoid derived drug, Sativex, is approved to treat MS spasticity and pain [297,298], and in
different animal models of MS, cannabinoid treatment based on cannabidiol solely, or cannabidiol
plus THC (Sativex), reduces the myelin injury, inflammation and functional impairment [299–301].
The modulation of 2-AG levels effectively reduces motor symptoms, along with inflammation and
demyelination [302,303]. Some of this protective effect is mediated by cytosolic Ca2+ modulation.
Either the inhibition of 2-AG degrading enzyme, or the direct administration of 2-AG preventing
intracellular Ca2+ increase via AMPARs, and the subsequent pattern of mitochondrial dysfunction
and ROS increase [302]. Similar results are obtained in cultured OL when CB1 receptor agonist are
administered after AMPAR activation, or K+- induced depolarization, with both producing a reduction
in intracellular Ca2+ [302,304] (Figure 1B). These processes might involve the activation of Gi/0 proteins,
the blockade of Kir or voltage-gated Ca2+ channels (VGCCs) [304,305]. The administration of the
phytocannabinoid cannabidiol (CBD), a promising therapeutic molecule, also modulates intracellular
Ca2+ via mechanisms involving mitochondria, and can, under specific conditions, induce OL cell
death [306]. In spite of the controversy concerning the deleterious effect of CBD on OL cell cultures,
some authors have identified a dose-dependent response [306,307]. Furthermore, CBD has been
reported to be oligoprotective after an inflammatory damage [307], and to reduce excitotoxicity in
several pathologies such as stroke or neonatal hypoxia-ischemia [58,308–310]. Results of our group
have proved this dual effect. While the exposure of mouse organotypic cerebellar slices to CBD resulted
in a reduction of the OL population; CBD applied before and during an excitotoxic insult was able to
reduce OL cell death (Ceprian M, Ng J, Fulton D, unpublished). Promising oligoprotective findings
from CBD treatments suggest that more research in this area are warranted. An important area for this
work relates to the mechanism of CBD action on glia, which at this time remains unclear.
After an excitotoxic insult, there is an increase of endocannabinoids and endocannabinoids-like
molecules, probably released by neurons [308,311]. Interestingly, the administration of the endocannabinoids
2-AG or anandamide (AEA) or synthetic cannabinoid agonist, HU-210, reduces cell death after AMPA
administration in a mixed culture of astrocytes and neurons [221,311]. HU-210 neuroprotective mechanism
are also seen in vivo and requires astrocytes and CB1 and CB2 activation [221]. AEA also exerts its
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neuroprotection via CB1 and CB2 receptors, and by preventing the AMPAR-induced downregulation of
astrocyte glutamate transporters GLAST and GLT-1, as evidenced in both primary cultures of astrocytes,
and an in vivo model of MS [311] (Figure 1B). In agreement with these results, the agonism of both
cannabinoid receptors by WIN55,212-2 increases GLAST and GLT-1 expression in the spinal cord of EAE
induced animals [312], while another study in the EAE model has found a decrease of AEA and 2-AG,
which due to the actions on GLAST and GLT-1 described above, would be expected contribute to glutamate
excitotoxicity [313] (Figure 1B).
Finally, the administration of the phytocannabinoids THC and CBD modulate the expression of
neuronal GluA2-AMPAR in rodent models of drug abuse [314,315]. Further research to analyze if
a similar AMPAR subunit modulation occurs after cannabinoid administration in excitotoxic models
could help to elucidate cannabinoid’s protective action on glial cells.
7. AMPAR-Stimulated Gene Expression in Glial Cells: Contributions to Injury and Disease?
Activity-dependent receptor-mediated gene expression, particularly immediate early genes (IEGs),
regulates key functions in the CNS including development and synaptic plasticity [316,317]. Gene
expression in glial cells can also regulated by neuronal activity, for example in astrocytes where
neuronally derived notch signals regulates a broad range of genes leading to alterations in astrocyte
development, metabolism and neurotransmitter uptake functions [318]. As described in Section 2.1
astrocytes express functional AMPAR that allow them to respond to glutamate released from neuronal
synapses. Given the broad range of astrocyte genes regulated by neuronal activity [318] it is tempting
to speculate on the potential of AMPAR to contribute to these actions. For example, AMPAR activation
on Bergmann glial cells leads to a downregulation in transcription of the glutamate transporter GLAST
via a mechanism involving Ca2+ influx, PKC signaling and the activation of the IEG c-jun [99]. GLAST
downregulation was observed with prolonged exposures to glutamate. Triggering of this regulatory
response during periods of elevated extracellular glutamate, as occurs in pathological conditions
such as MS [121], stroke and hypoxic-ischemia [4], could therefore lead to an amplification of the
pathophysiological levels of glutamate (Figure 2).
AMPAR have also been shown to regulate IEG in cortical cultures of OPC [44] where stimulation of
AMPAR induced a Ca2+-dependent upregulation in ngfi-a and other IEGs (Figure 1A). Ngfi-a (also known
as zif-268, egr-1 and krox-20) is implicated in regulation of the cell cycle [319], and is induced dramatically
in the brain in a depolarisation-dependent manner [320]. Thus Ngfi-a activation by AMPAR may
contribute to the regulation of OPC proliferation observed following modulation of neuronal activity and
AMPAR [41,148,210]. AMPAR stimulation inhibits OPC proliferation [210], thus pathological elevations
in glutamate concentrations could act to reduce the supply of remyelinating OPC. As discussed in
Section 3.3, excessive AMPAR activation injures OL lineage cells via Ca2+-dependent mechanisms
involving mitochondrial stress and the induction of pro-apoptotic Bcl-2 molecules [65,169,321].
Apoptosis is closely regulated by the induction of pro- and anti-apoptotic Bcl-2 genes [322,323],
so the pathways connecting pathophysiological AMPAR stimulation may provide an interesting range
of targets for therapeutic research. Related to this idea, we recently examined the transcriptional
events induced in OPC following pathophysiological AMPAR stimulation [45]. To focus our work we
searched for potential regulators of Gria4, the gene encoding GluA4, via an in silico analysis. Gria4
was an attractive target since it has prominent expression in OPC, and has been linked to excitotoxic
injury in other cell types [208]. From among the set of candidate regulators we selected NF-Y subunit b
(NF-Yb), a member of the NF-Y complex whose activity is closely associated with the regulation of
apoptototic cell death [88,324]. Experiments using an OPC cell line revealed that excitotoxic AMPAR
stimulation altered NF-Yb expression, modulated its binding to regulatory regions within Gria4, and
altered the expression of Gria4 transcripts. Thus NF-Yb is regulated by pathophysiological stimulation
of AMPAR leading to alterations in the expression of target genes. Further experiments using primary
OPC showed that excitotoxic stimulation produced a parallel increase in the expression of NF-Yb
and its target gene Gria4. Interestingly GluA4 protein is upregulated in OL in an in vivo hypoxia
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model [237], thus it is tempting to speculate on the involvement of NF-Yb in these actions. NF-Yb
is linked to the control of apoptosis [88,324] thus we performed a transcriptomic analysis to identify
genes that were differentially regulated by NF-Yb modulation and excitotoxicity. For this analysis we
compared the effects of a treatment with Garcinol, a compound that both blocked NF-Yb binding to
Gria4 and reduced cellular viability, with an excitotoxic AMPAR stimulation proven to injure OPC.
Both treatments induced transcriptional regulation in the same set of apoptotic genes underscoring
the link between NF-Y function, excitotoxic injury, and apoptosis in OPC (Figure 1B). As described in
this review, AMPAR are ubiquitous in neurons and glial cells so the clinical use of systemic AMPAR
blockade is likely to produce numerous side effects that may complicate the evaluation of therapeutic
outcomes. Cell-specific targeting could reduce these problems, but the technologies available are
not translatable, and in any case, AMPAR influence numerous physiological functions in glial cells
whose modulation may worsen disease conditions. Consequently, molecular targets downstream of
pathological AMPAR activation, for example those contained within the NF-Y transcriptome, represent
an attractive proposition for research aiming to provide protection against pathological conditions
involving AMPAR-mediated injury.
8. Summary
AMPAR are expressed widely by glial cells throughout the nervous system. Their activation
modulates numerous cellular actions in glia including ion channel function, gene expression, migration,
various aspects of growth and differentiation, and even the expression and subunit composition of
AMPAR themselves. Additionally, at the tissue level glial AMPAR influence homeostatic functions and
shape neuronal function by regulating myelin production and modulating synaptic function. Numerous
pathological conditions, including several notable neurological and neurodegenerative conditions,
involve dysregulation of extracellular glutamate levels. These conditions can lead to excessive AMPAR
stimulation triggering injury responses within glia and releasing additional excitotoxic signals in the
form of glutamate and cytokines. Glia are a key feature of the nervous system whose normal activities
maintain an environment that is optimal for healthy development and neuronal circuit activity, thus
the identification of therapeutic approaches capable of protecting glial functions and viability under
excitotoxic conditions are a critical target for future research.
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